Tag archive for ‘Medivation Inc.’
Initiation Report (MDVN, $17.09)
I am initiating coverage of Medivation based on my interest in their new drug for prostate cancer MDV 3100, which could be a major advance in therapy. I need to see more clinical data that substantiates the results seen in early stage studies before I recommend the stock. Stock Opinion I am not inclined […]